MAP2K7 and melanoma: Again, using a systematic approach, the combination of MEK and CDK4 inhibitors was found effective in preclinical NRAS-mutant melanoma models (Kwong et al, 2012), providing the basis for clinical combination trials (Johnson et al, 2014).